Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Turn Therapeutics Inc.NASDAQ: TTRX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables of $0 in Q1 FY2026
Q1 FY2026 net receivables was $0.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026.
- Net receivables increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Net Receivables vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 net receivables of $0 is the 6th highest of the 9 companies compared; the peer median is $1.39M.
- Net receivables amounts to 0.0% of total assets for TTRX, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $54.06M | +15171.8% | -12.6% | 29.0% | |
| Mar 2026 | $4.26M | -20.5% | -5.3% | 1.6% | |
| Mar 2026 | $3.66M | -23.5% | +39.3% | 10.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $2.72M | -42.9% | -13.3% | 4.1% |
| Apr 2026 | $56K | — | — | 0.4% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding TTRX) | $1.39M | -23.5% | -9.0% | 1.0% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.